151. [A case of leiomyosarcoma of prostate: multimodality therapy suppressed disease progression for long term].
- Author
-
Hayashi T, Nakai Y, Kakuta Y, Takayama H, Nakayama M, Nonomura N, Okumi M, and Nakao A
- Subjects
- Aged, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Docetaxel, Humans, Male, Taxoids administration & dosage, Gemcitabine, Leiomyosarcoma therapy, Prostatic Neoplasms therapy
- Abstract
A 67-year-old man presented with macroscopic hematuria. Transrectal prostatic needle biopsy was performed because of elevated prostate specific antigen (PSA) (3.85 ng/ml) and palpation of hard nodules at the prostate. Pathological diagnosis was leiomysarcoma. Computed tomography revealed several pulmonary metastases. Radical cysto-prostatectomy and construction of ileal conduct were performed. Adjuvant radiotherapy (50 Gy) was also performed. During follow-up, the size of the pulmonary metastases increased, and we decided to start systemic chemotherapy 7 months after surgery. The chemotherapy consisted of gemcitabine (900 mg/m2 on day 1 and day 8), and docetaxel (100 mg/m2 on day 8). After eight courses, there was 20% reduction in the size of some pulmonary metastases. He remained alive 21 months after diagnosis.
- Published
- 2010